Genetic, biochemical and neuropathological studies support the idea that cerebral elevation and accumulation of amyloid beta-peptide (Abeta) is an early and necessary step in AD pathogenesis. Abeta is generated from the amyloid beta-protein precursor (APP) by two proteolytic cleavages mediated by beta- and gamma-secretases. Mutations in the APP and presenilin genes cause rare early-onset forms of familial Alzheimer's disease (FAD), which shares many pathological features with the more common sporadic AD. Although FAD-associated genes (e.g. PS and APP) are expressed throughout the brain, early and most severe AD-associated neurodegenerative changes manifest in selective populations of neurons, e.g. neurons in entorhinal cortex and basal forebrain. Thus, additional cellular factors may contribute to selective neuronal vulnerability in AD. The hippocampus, a vital brain region for memory function, consists of multiple sub-regions each containing a unique population of neurons. The various subregions of hippocampus seem to be differentially affected in AD: for instance, entorhinal cortex is the most severely affected area, while dentate gyrus is relatively spared. To examine the underlying molecular mechanisms of selective vulnerability associated with common sporadic AD, we have performed carefully controlled microarray analyses to identify genes that are selectively up- or down-regulated in AD entorhinal cortex relative to dentate gyrus (in the same patient). Our microarray analyses revealed that VPS35p, a putative endosome/TGN trafficking molecule, is selectively upregulated in AD entorhinal cortex. Parallel analyses revealed that suppression of endogenous VPS35p using RNA interference (RNAi) in APP-expressing cells selectively lowers AP generation, suggesting that VPS35p is a modulatory factor in Abeta biogenesis. In light of our findings, the overall goal of this proposal is to perform molecular and functional characterization of VPS35p to delineate the role of this protein in APP processing and selective cellular dysfunction of entorhinal cortex in sporadic AD. The successful completion of this project will help identify cellular pathways that are directly involved in Abeta biogenesis and selective neuronal degeneration in AD entorhinal cortex, and may lead to development of a clinically valuable assay system for novel therapeutic reagents.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG008702-17
Application #
7309721
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-06-01
Budget End
2007-05-31
Support Year
17
Fiscal Year
2006
Total Cost
$125,000
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Qureshi, Yasir H; Patel, Vivek M; Berman, Diego E et al. (2018) An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 38:
Reitz, Christiane (2018) Retromer Dysfunction and Neurodegenerative Disease. Curr Genomics 19:279-288
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Tariciotti, Leonardo; Casadei, Matthew; Honig, Lawrence S et al. (2018) Clinical Experience with Cerebrospinal Fluid A?42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis 65:1417-1425
Masucci, Michael D; Lister, Amanda; Corcoran, Cheryl M et al. (2018) Motor Dysfunction as a Risk Factor for Conversion to Psychosis Independent of Medication Use in a Psychosis-Risk Cohort. J Nerv Ment Dis 206:356-361
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104

Showing the most recent 10 out of 640 publications